Sernova Completes Acquisition of Cellular Local Immune Protection Technology
Sernova Corp., a clinical-stage regenerative medicine therapeutics company, is pleased to announce it has completed the acquisition of cellular local immune protection technology from Converge Biotech, Inc. (“Converge”). “This acquisition is a strategic accelerator for expansion of Sernova’s total regenerative medicine cell therapy therapeutics platform,” stated Dr. Philip Toleikis, Sernova’s President and Chief Executive Officer.…